Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of siRNA Therapies for Prevention?
| Autor: | Ballantyne CM; Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. Electronic address: cmb@bcm.edu., Minhas AMK; Department of Medicine, Baylor College of Medicine, Houston, Texas, USA., Orringer CE; NCH Rooney Heart Institute, Naples, Florida, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of the American College of Cardiology [J Am Coll Cardiol] 2023 Dec 12; Vol. 82 (24), pp. 2262-2264. |
| DOI: | 10.1016/j.jacc.2023.10.020 |
| Abstrakt: | Competing Interests: Funding Support and Author Disclosures Dr Ballantyne has received institutional grant/research support and consulting fees from Novartis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|